CLDN5 and stroke disorder: Herein, we have demonstrated that a biomarker panel of TJ proteins (OCLN, Claudin-5, and ZO-1) combined with a stroke severity scale, NIHSS, can be a good prediction model to differentiate between IS patients and SMs.